Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, and certain of our subsidiaries have executed settlement agreement with 'The Medicines Company, USA' settling the lawsuit filed in the United States against the company and its subsidiaries regarding submission of an Abbreviated New Drug Application (ANDA) by one of our subsidiaries, for a generic version of Angiomax, Bivaliruding injection.

This product is a direct thrombin inhibitor indicated for use as an anticoagulant.

Shares of the company gained Rs 56.3, or 5.51%, to settle at Rs 1,078.55. The total volume of shares traded was 279,767 at the BSE (Wednesday).